FR2027273A1 - Methyl xanthines having cardiac activityh - Google Patents

Methyl xanthines having cardiac activityh

Info

Publication number
FR2027273A1
FR2027273A1 FR6945119A FR6945119A FR2027273A1 FR 2027273 A1 FR2027273 A1 FR 2027273A1 FR 6945119 A FR6945119 A FR 6945119A FR 6945119 A FR6945119 A FR 6945119A FR 2027273 A1 FR2027273 A1 FR 2027273A1
Authority
FR
France
Prior art keywords
hydroxy
theophylline
isopropylaminopropane
methylxanthine
theobromine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR6945119A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Original Assignee
CH Boehringer Sohn AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CH Boehringer Sohn AG and Co KG filed Critical CH Boehringer Sohn AG and Co KG
Publication of FR2027273A1 publication Critical patent/FR2027273A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions contain (1) at least one methylxanthine deriv. such as a theophylline, a theobromine, a cafeine or a paraxanthine or one of their salts and which carry a side-chain to improve their solubility in an aqs. medium such as a hydroxyalkyl, aminoalkyl or hydroxyaminoalkyl group, and (2) a beta-receptor blocking agent such as a 1-hydroxy-2-hydroxy-3-aminopropane or a 1-aryl-1-hydroxy-2-amino ethane and their salts with physiologically acceptable acids. The compositions have cardiac activity and are administered orally or parenterally. Suitable methylxanthine derivs. are theophylline, 7-(betahydroxyethyl)theophylline, 1-(betabenzylaminoethyl)theobromine. Suitable beta-receptor blocking agents are 1-(1-naphthoxy)-2-hydroxy-3-isopropylaminopropane, 1-(2-methoxyphenoxy)-2-hydro-3-isopropylaminopropane, 1-(4-methanesulphonylaminophenyl)-1-hydroxy-2-isopropylaminoethan- e.
FR6945119A 1968-12-28 1969-12-26 Methyl xanthines having cardiac activityh Withdrawn FR2027273A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19681817346 DE1817346A1 (en) 1968-12-28 1968-12-28 Cardiac preparations based on methylanthines

Publications (1)

Publication Number Publication Date
FR2027273A1 true FR2027273A1 (en) 1970-09-25

Family

ID=5717551

Family Applications (1)

Application Number Title Priority Date Filing Date
FR6945119A Withdrawn FR2027273A1 (en) 1968-12-28 1969-12-26 Methyl xanthines having cardiac activityh

Country Status (4)

Country Link
BE (1) BE743721A (en)
DE (1) DE1817346A1 (en)
FR (1) FR2027273A1 (en)
NL (1) NL6919408A (en)

Also Published As

Publication number Publication date
DE1817346A1 (en) 1970-07-23
NL6919408A (en) 1970-06-30
BE743721A (en) 1970-06-24

Similar Documents

Publication Publication Date Title
KR930702351A (en) Xanthine derivatives
ES440631A1 (en) Purine derivatives
DK150304C (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 9- (1,3-DIHYDROXY-2-PROPOXYMETHYL) GUANINE OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
Hokanson et al. Negro-white differences on the MMPI.
DK11391D0 (en) ALKOXY-4 (1H) -PYRIDON DERIVATIVES AND PHARMACOLOGICAL ACCEPTABLE SALTS THEREOF, THEIR PREPARATION AND USE
DK149046C (en) METHOD OF ANALOGUE FOR PREPARING LHRH ANALOGUE NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
ES8305363A1 (en) Topical formulations of 9-(2-hydroxyethoxymethyl) guanine.
ES483894A1 (en) Acid addition salts of 16-beta-monoquaternary ammonium derivatives of 2-beta, 16-beta-bis-piperidino-androstanes and pharmaceutical preparations containing same.
FR2027273A1 (en) Methyl xanthines having cardiac activityh
ATE137113T1 (en) ANTIVIRAL PHARMACEUTICAL OIL IN WATER EMULSION CONTAINING 9-((2-HYDROXYETHOXY)METHYL>-GUANINE (ACYCLOVIR) OR A SALT OR ESTER THEREOF
BE771672A (en) HIGH MOLECULAR WEIGHT MANNICH CONDENSATION PRODUCTS MODIFIED BY ALIPHATIC ACID AND SOLUBLE IN OIL
ZA907739B (en) Use of derivative of 1,3,7-trimethylxanthine for the treatment of memory disorders,intellectual disorders of ageing and alzheimer's disese
FR2310764A1 (en) ORAL-ADMINISTERED SOLID DRUG FORMS OF WATER-SOLUBLE XANTHINE DERIVATIVES
KR890003383A (en) Pharmaceutical formulation products and preparation methods and uses thereof
BE766492A (en) VACCINE TO IMMUNIZE POULTRY AGAINST MAREK'S DISEASE
DK160686A (en) TRI AND TETRACYCLIC COMPOUNDS
SE8803309D0 (en) ANTIVIRAL AGENTS
Thiersch Effect of 6-(1′-methyl-4′-nitro-5′-imidazolyl)-mercaptopurine and 2-amino-6-(1′-methyl-4′-nitro-5′-imidazolyl)-mercaptopurine on the rat litter in utero
Halle On Russian accentuation
GB1173322A (en) Pharmaceutical Compositions containing Proscillaridin A
Ancill et al. Oral caffeine augmentation of ECT.
JPS5770820A (en) Immunoregulating agent
ES342172A1 (en) Pharmaceutical Compositions Containing Alkaloids.
GB1417323A (en) Physiologically active xanthine compounds and compositions containing them
FR2395001A1 (en) Combined sofa and bed with storage unit - has seat backing onto storage unit to form integral piece into which bed retracts by sliding

Legal Events

Date Code Title Description
ST Notification of lapse